Evolent Health Earnings: What To Look For From EVH

Healthcare solutions company Evolent Health (NYSE:EVH) will be reporting earnings this Thursday before market hours. Here’s what to look for.

Evolent Health missed analysts’ revenue expectations last quarter, reporting revenues of $496.2 million, up 2.6% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates.

Is Evolent Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Evolent Health’s revenue to grow 34.3% year on year, a reversal from the 31.3% decrease it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Evolent Health has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Evolent Health’s peers in the healthcare technology segment, only Omnicell has reported results so far. It exceeded analysts’ revenue estimates, delivering year-on-year sales growth of 7.4%. The stock was down 14.6% on the results.

Investors in the healthcare technology segment have had steady hands going into earnings, with share prices up 1.4% on average over the last month. Evolent Health is down 46.1% during the same time and is heading into earnings with an average analyst price target of $5.83 (compared to the current share price of $3.10).

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.